Beam Therapeutics is trading 13% down now at $25.80, after falling from the September 4 close of $29.66; the immediate catalyst remains unclear.
- On September 8, the company released positive updated BEAM-302 data describing durable in-vivo correction and potential treatment for lung and liver manifestations of AATD.
- Available materials do not establish that announcement caused the decline; broader market pressure is mixed.